Skip to main content
SpringerLink
Log in

The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis

  • Meta- Analysis
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Introduction

Data on silent corticotroph tumor (SCT) are still heterogeneous and controversial. In this study, we aimed to compare the demographic, clinicopathological manifestations, postoperative complications, and patient outcomes of SCTs with other non-functioning pituitary neuroendocrine tumor (NFT) and functioning corticotroph tumor (FCT) or so-called Cushing disease adenoma.

Methods

We searched PubMed and Web of Science for data of interest. Odds ratio (OR), mean difference (MD), hazard ratio (HR), and their 95% confidence intervals (CI) were pooled using the random-effect model.

Results

Twenty-nine studies with 985 SCTs were included in meta-analyses. In comparison to other NFTs, SCTs were more commonly associated with female gender, younger age, cavernous sinus invasion, apoplexy, and radiotherapy administration. Postoperatively, SCT patients were more likely to experience hypocortisolism, new-onset visual disturbances, and a higher risk for tumor progression than other NFTs. We did not find any significant differences between SCT type I and type II. Compared to FCTs, SCTs were more likely male, older age, and had larger tumor sizes. The prevalence of a USP8 mutation was significantly higher in FCT than in SCT.

Conclusion

SCT was demographically, clinicopathologically, and prognostically distinct from other NFTs and FCTs. These tumors should be considered high-risk; appropriate treatment decisions and more stringent follow-up should be tailored to improve patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. D.N. Louis, A. Perry, P. Wesseling et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 23(8), 1231–1251 (2021)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. S.L. Asa, O. Mete, A. Perry, R.Y. Osamura, Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr. Pathol. 33(1), 6–26 (2022)

    Article  CAS  PubMed  Google Scholar 

  3. O. Mete, M.B. Lopes, Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr. Pathol. 28(3), 228–243 (2017)

    Article  CAS  PubMed  Google Scholar 

  4. H. Alahmadi, D. Lee, J.R. Wilson et al. Clinical features of silent corticotroph adenomas. Acta Neurochirurgica 154(8), 1493–1498 (2012)

    Article  PubMed  Google Scholar 

  5. K.J. Bradley, J.A.H. Wass, H.E. Turner, Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin. Endocrinol. 58(1), 59–64 (2003)

    Article  CAS  Google Scholar 

  6. H.Y. Cho, S.W. Cho, S.W. Kim, C.S. Shin, K.S. Park, S.Y. Kim, Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin. Endocrinol. 72(5), 648–653 (2010)

    Article  Google Scholar 

  7. O. Cohen-Inbar, Z.Y. Xu, C.C. Lee et al. Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study. J. Neuro-Oncol. 135(1), 67–74 (2017)

    Article  Google Scholar 

  8. B.A. Strickland, S. Shahrestani, R.G. Briggs et al. Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence. J. Neurosurg. 135(6), 1706–1713 (2021)

    Article  CAS  PubMed  Google Scholar 

  9. M.B.S. Lopes, The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 134(4), 521–535 (2017)

    Article  CAS  PubMed  Google Scholar 

  10. D. Moher, A. Liberati, J. Tetzlaff, D. Altman; PRISMA Group, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7), e1000097 (2009)

    Article  PubMed  PubMed Central  Google Scholar 

  11. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, M.R. Sydes, Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16 (2007)

    Article  PubMed  PubMed Central  Google Scholar 

  12. J.P. Higgins, S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat. Med. 21(11), 1539–1558 (2002)

    Article  PubMed  Google Scholar 

  13. G. Akkus, B. Karagun, N.E. Cetinalp et al. Clinical, hormonal, radiological and morphological comparison of patients with clinically evident Cushing’s disease and patients with silent corticotroph cell adenoma. Cukurova Med. J. 45(4), 1720–1732 (2020)

    Article  Google Scholar 

  14. T. Amano, T. Masumoto, D. Watanabe, et al. Differentiation of silent corticotroph pituitary neuroendocrine tumors (PitNETs) from non-functioning PitNETs using kinetic analysis of dynamic MRI. Jpn J Radiol. 2023.

  15. R.L. Batista, E.B. Trarbach, M.D. Marques et al. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile. World Neurosurg. 120, E241–E246 (2018)

    Article  PubMed  Google Scholar 

  16. M. Bujko, P. Kober, J. Boresowicz et al. USP8 mutations in corticotroph adenomas determine a distinct gene expression profile irrespective of functional tumour status. Eur. J. Endocrinol. 181(6), 615–627 (2019)

    Article  CAS  PubMed  Google Scholar 

  17. S. Castellnou, A. Vasiljevic, V. Lapras et al. SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors. Endocr. Connect. 9(3), 243–253 (2020)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. O. Cooper, A. Ben-Shlomo, V. Bonert, S. Bannykh, J. Mirocha, S. Melmed, Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm. Cancer 1(2), 80–92 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. A. Garcia-Martinez, A.C. Fuentes-Fayos, C. Fajardo, et al. Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors. J. Clin. Med. 9(6); (2020)

  20. A. Goyal-Honavar, S. Sarkar, H.S. Asha et al. A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary-specific transcription factors. Acta Neurochirurgica 163(11), 3143–3154 (2021)

    Article  PubMed  Google Scholar 

  21. I.H. Hewedi, W.M. Osman, M.M. El Mahdy, Differential expression of cyclin D1 in human pituitary tumors: relation to MIB-1 and p27/Kip1 labeling indices. J. Egypt Natl Canc Inst. 23(4), 171–179 (2011)

    Article  PubMed  Google Scholar 

  22. L. Huang, G. Fatterpekar, S. Charles, D. Golub, D. Zagzag, N. Agrawal, Clinical Course and Unique Features of Silent Corticotroph Adenomas. World Neurosurg. 161, E274–E281 (2022)

    Article  PubMed  Google Scholar 

  23. A.G. Ioachimescu, L. Eiland, V.S. Chhabra et al. Silent Corticotroph Adenomas: Emory University Cohort and Comparison With ACTH-Negative Nonfunctioning Pituitary Adenomas. Neurosurgery 71(2), 296–303 (2012)

    Article  PubMed  Google Scholar 

  24. A. Jahangiri, J.R. Wagner, M. Pekmezci et al. A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73(1), 8–17 (2013).

    Article  PubMed  Google Scholar 

  25. S.Z. Jiang, J.Y. Zhu, M. Feng et al. Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system. Pituitary 24(4), 564–573 (2021)

    Article  CAS  PubMed  Google Scholar 

  26. D. Kim, C.R. Ku, S.H. Park et al. Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas. World Neurosurg. 115, E464–E471 (2018)

    Article  PubMed  Google Scholar 

  27. F. Langlois, D.S.T. Lim, E. Varlamov et al. Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. Endocrine 58(3), 528–534 (2017)

    Article  CAS  PubMed  Google Scholar 

  28. H. Nishioka, N. Inoshita, O. Mete et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr. Pathol. 26(4), 349–355 (2015)

    Article  CAS  PubMed  Google Scholar 

  29. M. Pawlikowski, J. Kunert-Radek, M. Radek, "Silent"corticotropinoma. Neuro Endocrinol. Lett. 29(3), 347–350 (2008)

    PubMed  Google Scholar 

  30. L.G. Perez-Rivas, M. Theodoropoulou, F. Ferrau et al. The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing’s Disease. J. Clin. Endocrinol. Metab. 100(7), E997–E1004 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. R. Reddy, S. Cudlip, J.V. Byrne, N. Karavitaki, J.A. Wass, Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? Eur. J. Endocrinol. 165(5), 739–744 (2011)

    Article  CAS  PubMed  Google Scholar 

  32. T.R. Smith, M.M. Hulou, K.T. Huang et al. Complications after transsphenoidal surgery for patients with Cushing’s disease and silent corticotroph adenomas. Neurosurg. Focus. 38(2), E12 (2015)

    Article  PubMed  Google Scholar 

  33. T. Tateno, H. Izumiyama, M. Doi, T. Akashi, K. Ohno, Y. Hirata, Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma. Endocr. J. 54(5), 777–782 (2007)

    Article  CAS  PubMed  Google Scholar 

  34. A.K. Watts, A. Easwaran, P. McNeill, Y.Y. Wang, W.J. Inder, C. Caputo, Younger age is a risk factor for regrowth and recurrence of nonfunctioning pituitary macroadenomas: Results from a single Australian centre. Clin. Endocrinol. (Oxf.) 87(3), 264–271 (2017)

    Article  PubMed  Google Scholar 

  35. Z.Y. Xu, S. Ellis, C.C. Lee et al. Silent Corticotroph Adenomas After Stereotactic Radiosurgery: A Case-Control Study. Int. J. Radiat. Oncol. Biol. Phys. 90(4), 903–910 (2014)

    Article  PubMed  Google Scholar 

  36. K.Y. Zhang, X.F. Shou, H. Chen et al. Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases. Front. Endocrinol. (Lausanne) 11, 608691 (2021)

    Article  PubMed  Google Scholar 

  37. O. Cooper, Silent corticotroph adenomas. Pituitary 18(2), 225–231 (2015)

    Article  PubMed  PubMed Central  Google Scholar 

  38. A. Fountas, A. Lavrentaki, A. Subramanian, K.A. Toulis, K. Nirantharakumar, N. Karavitaki, Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 104(4), 1039–1048 (2018)

    Google Scholar 

  39. N.F. Lenders, A.C. Wilkinson, S.J. Wong et al. Transcription factor immunohistochemistry in the diagnosis of pituitary tumours. Eur. J. Endocrinol. 184(6), 891–901 (2021)

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Trang Le and Thoa Le (University of Medicine and Pharmacy at Ho Chi Minh City) for their assistance with the abstract screening.

Author contributions

H.G.V.: conceptualization, data curation, formal analysis, investigation, methodology, project administration, software, validation, writing original, review, and editing. I.F.D.: conceptualization, project administration, validation, review, editing, and supervisions. All authors have read and approved the manuscript.

Author information

Authors and Affiliations

  1. Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, 52242, US

    Huy Gia Vuong

  2. Department of Neurosurgery, Oklahoma University Health Sciences Center, Oklahoma City, OK, 73104, US

    Ian F. Dunn

Authors
  1. Huy Gia Vuong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian F. Dunn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian F. Dunn.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vuong, H.G., Dunn, I.F. The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis. Endocrine 82, 527–535 (2023). https://doi.org/10.1007/s12020-023-03449-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-023-03449-w

Keywords

Search

Navigation